Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.92 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.92 |
| ▸ | ADH1B | P00325 | 4/20 | 0.50 |
| ▸ | ADH1C | P00326 | 4/20 | 0.50 |
| ▸ | ADH1A | P07327 | 4/20 | 0.50 |
| ▸ | ADH4 | P08319 | 2/20 | 0.50 |
| ▸ | ADH7 | P40394 | 3/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL998135 | 1.00 | ALDH1A1 (0.92) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL18657086 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL21375316 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL2397472 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24771540 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24839013 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL24771539 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL25122871 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL20733078 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A | |
| SCHEMBL1000021 | 0.96 | ALDH1A1 (1.00) | ALDH1A1HSD17B10ADH1BADH1CADH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2963010-B1 | Electronic device and compound | NOVALED GMBH (DE) | 2018-02-21 | — | — | EP | disclosed |
| US-RE45183-E1 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2014-10-07 | — | — | US | disclosed |
| US-8435980-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8263634-B2 | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK A/S (DK) | 2012-09-11 | — | — | US | disclosed |
| CN-102516240-A | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-06-27 | — | — | CN | disclosed |
| EP-2444397-A1 | Heteroaryl-ureas and their use as glucokinase activators | Novo Nordisk A/S (DK) | 2012-04-25 | — | — | EP | disclosed |
| CN-1910166-B | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-01-04 | — | — | CN | disclosed |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2011-03-10 | — | — | US | disclosed |
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-01-20 | — | — | US | disclosed |
| US-7872139-B2 | e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes | NOVO NORDISK A/S (DK) | 2011-01-18 | — | — | US | disclosed |
| CN-1910166-A | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| EP-1723128-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005066145-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | NOVO NORDISK A/S (DK) | 2005-07-21 | — | — | WO | disclosed |
| EP-0680478-A1 | N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE 4H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-11-08 | — | — | EP | disclosed |
| EP-0670838-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO 4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1995-09-13 | — | — | EP | disclosed |
| US-5359073-A | Substituted-phenyl (N,N'-cycloalkyl/alkyl carboxamide)-1H/3H-imidazo[4,5-b]pyridine compounds as PAF antagonists | G. D. SEARLE & CO. (US) | 1994-10-25 | — | — | US | disclosed |
| WO-1994017063-A1 | N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE 4H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994012500-A1 | SUBSTITUTED-PHENYL(N,N'-CYCLOALKYL/ALKYL CARBOXAMIDE)-1H/3H-IMIDAZO[4,5-b]PYRIDINE COMPOUNDS AS PAF ANTAGONISTS | G.D. SEARLE & CO. (US) | 1994-06-09 | — | — | WO | disclosed |
| US-5302601-A | Useful in the treatment of diseases mediated by platelet activating factor | G. D. SEARLE & CO. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5262426-A | Treatment of cardiovascular disorders, antiinflammatory agents | G. D. SEARLE & CO. (US) | 1993-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015173-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | ALDH1A1 2908/4885HSD17B10 3601/4885ADH1B 3911/4885 |
| US-20110060019-A1 | HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS | GCK, HK1, HK2 | ALDH1A1 1548/4885HSD17B10 675/4885ADH1B 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.